SYNTHESIS AND ANTINEOPLASTIC PROPERTIES OF AN ETHER GLYCEROPHOSPHONOCHOLINE, AN ANALOG OF ET-18-OCH3-GPC

被引:7
作者
SALARI, H
HOWARD, S
BITTMAN, R
机构
[1] LIPASE BIOTECH INC, VANCOUVER, BC, CANADA
[2] CUNY QUEENS COLL, DEPT CHEM & BIOCHEM, FLUSHING, NY 11367 USA
关键词
D O I
10.1016/0006-291X(92)91237-K
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A glycerophosphonocholine analog of the ether-linked lipid, rac-1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine (ET-18-OCH3-GPC), was synthesized in which the head group is nonhydrolyzable by phospholipase C. The phosphonate analog used in this study is rac-3-octadecyloxy-2-methoxy-propyl-phosphonocholine, C18H37OCH2CH(OCH3)CH2P(O)(O)OCH2CH2N+(CH3)3. The activity of the synthetic phosphonate was tested in the human leukemic cell line, HL-60, and the human undifferentiated cervical carcinoma, C-41. The glycerophosphonocholine inhibited [3H]thymidine uptake by HL-60 cells with an EC50 value of 5-7 μM. The glycerophosphate ET-18-OCH3-GPC had an EC50 value of approximately 2 μM against HL-60 cells. The EC50 values estimated from cell viability experiments were similar to that for [3H]thymidine uptake. The EC50 value for C-41 cells was about 10-15 μM. The data demonstrate that the glycerophosphonocholine is a promising anticancer drug for the treatment of both leukemia and solid tumors. Furthermore, the data demonstrate that phospholipase C-catalyzed hydrolysis of ET-18-OCH3-GPC does not play an important role in the cytotoxic action of the ether-linked glycerolipids. © 1992.
引用
收藏
页码:603 / 608
页数:6
相关论文
共 16 条
[1]  
AUERSPERG N, 1989, CANCER RES, V49, P3007
[2]  
BERDEL WE, 1992, P AM ASS CANCER RE A, P2482
[3]  
DEROO PW, 1976, CHEM PHYS LIPIDS, V16, P60
[4]   METABOLISM OF ETHER PHOSPHOLIPIDS AND ANALOGS IN NEOPLASTIC-CELLS [J].
FLEER, EAM ;
UNGER, C ;
KIM, DJ ;
EIBL, H .
LIPIDS, 1987, 22 (11) :856-861
[5]   SYNTHESIS AND ANTINEOPLASTIC PROPERTIES OF ETHER-LINKED THIOGLYCOLIPIDS [J].
GUIVISDALSKY, PN ;
BITTMAN, R ;
SMITH, Z ;
BLANK, ML ;
SNYDER, F ;
HOWARD, S ;
SALARI, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (09) :2614-2621
[6]  
KHANAVKAR B, 1989, CONTRIB ONCOL, V37, P224
[7]  
KRAMER IM, 1989, J BIOL CHEM, V264, P5876
[8]  
MUNDER PG, 1990, CHEM IMMUNOL, V49, P206
[9]  
POWIS G, 1992, CANCER RES, V52, P2835
[10]  
ROSENTHAL AF, 1975, TETRAHEDRON LETT, P977